Globally, the prevalence of nonalcoholic steatohepatitis (NASH) is rapidly growing. In the U.S. it is now the second leading indicator for liver transplantation and one of the top three causes of liver cancer. In this video, Dr. Zobair M. Younossi, Professor and Chairman of the Department of Medicine at Inova Fairfax Hospital in Falls Church, Virginia, discusses the epidemiology of nonalcoholic fatty liver disease (NAFLD), addressing why there is a global need for more awareness and why the current approach to clinical care needs to change.
Addressing the Rising Prevalence of Non-alcoholic Fatty Liver Disease
|16.8.2019